Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors.
Cardiovascular Agents
/ therapeutic use
Cost-Benefit Analysis
Diabetes Mellitus, Type 2
/ complications
Drug Therapy, Combination
Heart Failure
/ drug therapy
Humans
Multicenter Studies as Topic
Practice Guidelines as Topic
Quality of Life
Randomized Controlled Trials as Topic
Sodium-Glucose Transporter 2 Inhibitors
/ adverse effects
Stroke Volume
/ drug effects
Journal
Drugs
ISSN: 1179-1950
Titre abrégé: Drugs
Pays: New Zealand
ID NLM: 7600076
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
accepted:
19
05
2021
pubmed:
24
6
2021
medline:
16
12
2021
entrez:
23
6
2021
Statut:
ppublish
Résumé
Sodium-glucose cotransporter 2 (SGLT2) inhibitors were first developed as glucose-lowering therapies for the treatment of diabetes. However, these drugs have now been recognised to prevent worsening heart-failure events, improve health-related quality of life, and reduce mortality in people with heart failure with reduced ejection fraction (HFrEF), including those both with and without diabetes. Despite robust clinical trial data demonstrating favourable outcomes with SGLT2 inhibitors for patients with HFrEF, there is a lack of familiarity with the HF indication for these drugs, which have been the remit of diabetologists to date. In this article we use consensus expert opinion alongside the available evidence and label indication to provide support for the healthcare community treating people with HF regarding positioning of SGLT2 inhibitors within the treatment pathway. By highlighting appropriate prescribing and practical considerations, we hope to encourage greater, and safe, use of SGLT2 inhibitors in this population.
Identifiants
pubmed: 34160822
doi: 10.1007/s40265-021-01538-6
pii: 10.1007/s40265-021-01538-6
doi:
Substances chimiques
Cardiovascular Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1243-1255Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215–25. https://doi.org/10.1007/s00125-016-4157-3 .
doi: 10.1007/s00125-016-4157-3
pubmed: 27878313
Saisho Y. SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases. 2020. https://doi.org/10.3390/diseases8020014 .
doi: 10.3390/diseases8020014
pubmed: 32403420
pmcid: 7349723
Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262–74. https://doi.org/10.7326/0003-4819-159-4-201308200-00007 .
doi: 10.7326/0003-4819-159-4-201308200-00007
pubmed: 24026259
Ghosh RK, Ghosh GC, Gupta M, Bandyopadhyay D, Akhtar T, Deedwania P, et al. Sodium glucose co-transporter 2 inhibitors and heart failure. Am J Cardiol. 2019;124(11):1790–6. https://doi.org/10.1016/j.amjcard.2019.08.038 .
doi: 10.1016/j.amjcard.2019.08.038
pubmed: 31627834
Staels B. Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. Am J Cardiol. 2017;120(1s):S28-s36. https://doi.org/10.1016/j.amjcard.2017.05.013 .
doi: 10.1016/j.amjcard.2017.05.013
pubmed: 28606341
Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108–17. https://doi.org/10.1007/s00125-018-4670-7 .
doi: 10.1007/s00125-018-4670-7
pubmed: 30132036
Filippatos TD, Liontos A, Papakitsou I, Elisaf MS. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019;131(2):82–8. https://doi.org/10.1080/00325481.2019.1581971 .
doi: 10.1080/00325481.2019.1581971
pubmed: 30757937
Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397–402. https://doi.org/10.1056/NEJMoa020265 .
doi: 10.1056/NEJMoa020265
pubmed: 12409541
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38-360. https://doi.org/10.1161/cir.0000000000000350 .
doi: 10.1161/cir.0000000000000350
pubmed: 26673558
British Heart Foundation. UK factsheet. 2020. https://www.bhf.org.uk/what-we-do/our-research/heart-statistics . Accessed 1 Dec 2020.
Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171(3):368–76. https://doi.org/10.1016/j.ijcard.2013.12.028 .
doi: 10.1016/j.ijcard.2013.12.028
pubmed: 24398230
Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace. 2011;13(Suppl 2):ii13–7. https://doi.org/10.1093/europace/eur081 .
Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail. 2015;3(2):136–45. https://doi.org/10.1016/j.jchf.2014.08.004 .
doi: 10.1016/j.jchf.2014.08.004
pubmed: 25660838
Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. Circ Res. 2019;124(1):121–41. https://doi.org/10.1161/circresaha.118.311371 .
doi: 10.1161/circresaha.118.311371
pubmed: 30605420
pmcid: 6447311
Rosano GM, Vitale C, Seferovic P. Heart failure in patients with diabetes mellitus. Card Fail Rev. 2017;3(1):52–5. https://doi.org/10.15420/cfr.2016:20:2 .
doi: 10.15420/cfr.2016:20:2
pubmed: 28785476
pmcid: 5494155
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720 .
doi: 10.1056/NEJMoa1504720
pubmed: 26378978
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. https://doi.org/10.1056/NEJMoa1611925 .
doi: 10.1056/NEJMoa1611925
pubmed: 28605608
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoa1812389 .
doi: 10.1056/NEJMoa1812389
Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo Jack S, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the vertis cv trial. Circulation. 2020. https://doi.org/10.1161/circulationaha.120.050255 .
doi: 10.1161/circulationaha.120.050255
pubmed: 33186063
pmcid: 7717477
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303 .
doi: 10.1056/NEJMoa1911303
pubmed: 31535829
pmcid: 31535829
Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE, et al. Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiol. 2021. https://doi.org/10.1001/jamacardio.2020.7585 .
doi: 10.1001/jamacardio.2020.7585
pubmed: 33595593
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation. 2020;141(2):90–9. https://doi.org/10.1161/circulationaha.119.044138 .
doi: 10.1161/circulationaha.119.044138
pubmed: 31736335
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang CE, Tereshchenko S, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation. 2020;141(2):100–11. https://doi.org/10.1161/circulationaha.119.044133 .
doi: 10.1161/circulationaha.119.044133
McEwan P, Darlington O, McMurray JJV, Jhund PS, Docherty KF, Böhm M, et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. Eur J Heart Fail. 2020. https://doi.org/10.1002/ejhf.1978 .
doi: 10.1002/ejhf.1978
pubmed: 32749733
AJMC. FDA approves Dapagliflozin to treat heart failure, breaking new ground in SGLT2 competition. 2020. https://www.ajmc.com/view/fda-approves-dapagliflozin-to-treat-heart-failure-breaking-new-ground-in-sglt2-competition . Accessed 1 Dec 2020.
AstraZeneca. Forxiga approved in Japan for chronic heart failure. 2020. https://www.astrazeneca.com/media-centre/press-releases/2020/forxiga-approved-in-japan-for-heart-failure.html . Accessed 1 Dec 2020.
European Medicines Agency. Forxiga: EPAR—medicine overview. 2020. https://www.ema.europa.eu/en/documents/overview/forxiga-epar-medicine-overview_en.pdf . Accessed 1 Dec 2020.
National Institute for Health and Care Excellence. Technology appraisal guidance [TA679]: Dapagliflozin for treating chronic heart failure with reduced ejection fraction. 2021. https://www.nice.org.uk/guidance/ta679 . Accessed 26 Feb 2021.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24. https://doi.org/10.1056/NEJMoa2022190 .
doi: 10.1056/NEJMoa2022190
pubmed: 32865377
pmcid: 32865377
Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England). 2020;396(10254):819–29. https://doi.org/10.1016/s0140-6736(20)31824-9 .
doi: 10.1016/s0140-6736(20)31824-9
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306. https://doi.org/10.1056/NEJMoa1811744 .
doi: 10.1056/NEJMoa1811744
pubmed: 30990260
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. https://doi.org/10.1056/NEJMoa2024816 .
doi: 10.1056/NEJMoa2024816
pubmed: 32970396
Iyngkaran P, Thomas M, Majoni W, Anavekar NS, Ronco C. Comorbid heart failure and renal impairment: epidemiology and management. Cardiorenal Med. 2012;2(4):281–97. https://doi.org/10.1159/000342487 .
doi: 10.1159/000342487
pubmed: 23381594
pmcid: 3551393
Chambergo-Michilot D, Tauma-Arrué A, Loli-Guevara S. Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: a systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2021;32:100690. https://doi.org/10.1016/j.ijcha.2020.100690 .
doi: 10.1016/j.ijcha.2020.100690
pubmed: 33335975
Caparrotta TM, Greenhalgh AM, Osinski K, Gifford RM, Moser S, Wild SH, et al. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) exposure and outcomes in type 2 diabetes: a systematic review of population-based observational studies. Diabetes Ther. 2021;12(4):991–1028. https://doi.org/10.1007/s13300-021-01004-2 .
doi: 10.1007/s13300-021-01004-2
pubmed: 33665777
pmcid: 7994468
Shah A, Gandhi D, Srivastava S, Shah KJ, Mansukhani R. Heart failure: a class review of pharmacotherapy. P t. 2017;42(7):464–72.
pubmed: 28674474
pmcid: 5481297
National Institute for Health and Care Excellence. NICE guideline [NG106]: Chronic heart failure in adults: diagnosis and management. 2018. https://www.nice.org.uk/guidance/ng106 . Accessed 1 Dec 2020.
National Institute for Health and Care Excellence. Technology appraisal guidance [TA388]: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction. 2016. https://www.nice.org.uk/guidance/ta388 . Accessed 1 Dec 2020.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077 .
doi: 10.1056/NEJMoa1409077
pubmed: 25176015
pmcid: 25176015
Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet (London, England). 2020;396(10244):121–8. https://doi.org/10.1016/s0140-6736(20)30748-0 .
doi: 10.1016/s0140-6736(20)30748-0
Paolillo S, Dell’Aversana S, Esposito I, Poccia A, Perrone FP. The use of β-blockers in patients with heart failure and comorbidities: doubts, certainties and unsolved issues. Eur J Intern Med. 2021. https://doi.org/10.1016/j.ejim.2021.03.035 .
doi: 10.1016/j.ejim.2021.03.035
pubmed: 33941435
Borer JS. Angiotensin-converting enzyme inhibition: a landmark advance in treatment for cardiovascular diseases. Eur Heart J Suppl. 2007;9(suppl_E):E2–9.
Ruschitzka F, Taddei S. Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection? Eur Heart J. 2012;33(16):1996–8. https://doi.org/10.1093/eurheartj/ehs108 .
doi: 10.1093/eurheartj/ehs108
pubmed: 22659198
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486 .
doi: 10.1093/eurheartj/ehz486
Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112(16):2426–35. https://doi.org/10.1161/circulationaha.105.582320 .
doi: 10.1161/circulationaha.105.582320
pubmed: 16143696
pmcid: 16143696
Sliwa K, Norton GR, Kone N, Candy G, Kachope J, Woodiwiss AJ, et al. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol. 2004;44(9):1825–30. https://doi.org/10.1016/j.jacc.2004.05.087 .
doi: 10.1016/j.jacc.2004.05.087
pubmed: 15519014
Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D, et al. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC Heart Fail. 2019;6(2):280–90. https://doi.org/10.1002/ehf2.12402 .
doi: 10.1002/ehf2.12402
pubmed: 30629342
pmcid: 6437434
Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, et al. Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom. J Am Heart Assoc. 2019;8(22):e012655. https://doi.org/10.1161/jaha.119.012655 .
doi: 10.1161/jaha.119.012655
pubmed: 31711387
pmcid: 6915283
Palaka E, Grandy S, Darlington O, McEwan P, van Doornewaard A. Associations between serum potassium and adverse clinical outcomes: a systematic literature review. Int J Clin Pract. 2020;74(1):e13421. https://doi.org/10.1111/ijcp.13421 .
doi: 10.1111/ijcp.13421
pubmed: 31532067
McEwan P, Hurst M, Hoskin L, Badora K, Sugrue D, James G et al. The relationship between duration of heart failure, serum potassium concentration and adverse clinical outcomes. Eur Heart J. 2020;41(Supplement_2):ehaa946.0943.
Reed JW. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag. 2016;12:393–405. https://doi.org/10.2147/vhrm.S111991 .
doi: 10.2147/vhrm.S111991
pubmed: 27822054
pmcid: 5089867
Evans M, Hicks D, Patel D, Patel V, McEwan P, Dashora U. Optimising the benefits of SGLT2 inhibitors for type 1 diabetes. Diabetes Ther. 2020;11(1):37–52. https://doi.org/10.1007/s13300-019-00728-6 .
doi: 10.1007/s13300-019-00728-6
pubmed: 31813092
Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20030629 .
doi: 10.3390/ijms20030629
pubmed: 31752185
pmcid: 6888396
Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017. https://doi.org/10.1161/jaha.116.004007 .
doi: 10.1161/jaha.116.004007
pubmed: 28546454
pmcid: 5669140
Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol. 2018;71(5):471–6. https://doi.org/10.1016/j.jjcc.2017.12.004 .
doi: 10.1016/j.jjcc.2017.12.004
pubmed: 29415819
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752–72. https://doi.org/10.1161/circulationaha.116.021887 .
doi: 10.1161/circulationaha.116.021887
pubmed: 27470878
Thong KY, Yadagiri M, Barnes DJ, Morris DS, Chowdhury TA, Chuah LL, et al. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: the ABCD nationwide dapagliflozin audit. Prim Care Diabetes. 2018;12(1):45–50. https://doi.org/10.1016/j.pcd.2017.06.004 .
doi: 10.1016/j.pcd.2017.06.004
pubmed: 28669625
Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management. Metabolism. 2016;65(4):507–21. https://doi.org/10.1016/j.metabol.2015.12.007 .
doi: 10.1016/j.metabol.2015.12.007
pubmed: 26975543
Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44(4):375–93. https://doi.org/10.3109/07853890.2011.560181 .
doi: 10.3109/07853890.2011.560181
pubmed: 21495788
Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43. https://doi.org/10.1186/1741-7015-11-43 .
doi: 10.1186/1741-7015-11-43
pubmed: 23425012
pmcid: 3606470
Ramírez-Rodríguez AM, González-Ortiz M, Martínez-Abundis E. Effect of Dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. Exp Clin Endocrinol Diabetes. 2020;128(8):506–11. https://doi.org/10.1055/a-0664-7583 .
doi: 10.1055/a-0664-7583
pubmed: 30149417
Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–82. https://doi.org/10.1111/dom.12054 .
doi: 10.1111/dom.12054
pubmed: 23279307
pmcid: 3593184
Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet (London, England). 2013;382(9896):941–50. https://doi.org/10.1016/s0140-6736(13)60683-2 .
doi: 10.1016/s0140-6736(13)60683-2
Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring). 2014;22(4):1042–9. https://doi.org/10.1002/oby.20663 .
doi: 10.1002/oby.20663
Hollander P, Bays HE, Rosenstock J, Frustaci ME, Fung A, Vercruysse F, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care. 2017;40(5):632–9. https://doi.org/10.2337/dc16-2427 .
doi: 10.2337/dc16-2427
pubmed: 28289041
List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–7. https://doi.org/10.2337/dc08-1863 .
doi: 10.2337/dc08-1863
pubmed: 19114612
Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219–30. https://doi.org/10.1007/s40265-019-1057-0 .
doi: 10.1007/s40265-019-1057-0
pubmed: 30701480
pmcid: 6394798
Lundkvist P, Sjöström CD, Amini S, Pereira MJ, Johnsson E, Eriksson JW. Dapagliflozin once-daily and exenatide once-weekly dual therapy: a 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes Obes Metab. 2017;19(1):49–60. https://doi.org/10.1111/dom.12779 .
doi: 10.1111/dom.12779
pubmed: 27550386
Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinol Metab (Seoul). 2019;34(3):247–62. https://doi.org/10.3803/EnM.2019.34.3.247 .
doi: 10.3803/EnM.2019.34.3.247
pubmed: 31565876
pmcid: 6769337
National Institute for Health and Care Excellence. Clinical guideline [CG187]: acute heart failure: diagnosis and management. 2014. https://www.nice.org.uk/guidance/cg187/ . Accessed 1 Dec 2020.
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2030183 .
doi: 10.1056/NEJMoa2030183
pubmed: 33200892
pmcid: 33200892
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2030186 .
doi: 10.1056/NEJMoa2030186
pubmed: 33200892
pmcid: 33200892
Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-preserved trial. Eur J Heart Fail. 2019;21(10):1279–87. https://doi.org/10.1002/ejhf.1596 .
doi: 10.1002/ejhf.1596
pubmed: 31523904
Williams DM, Evans M. Dapagliflozin for heart failure with preserved ejection fraction: will the deliver study deliver? Diabetes Ther. 2020;11(10):2207–19. https://doi.org/10.1007/s13300-020-00911-0 .
doi: 10.1007/s13300-020-00911-0
pubmed: 32852697
pmcid: 7509021